Vol 16, No 5 (2021)
Conference report / Report
Published online: 2021-10-31
Advances in heart failure pharmacotherapy and cardio-vascular prevention: reports from The Congress of European Society of Cardiology 2020
1
, 1
, 1
DOI: 10.5603/FC.2021.0050
Folia Cardiologica 2021;16(5):348-352.
Abstract
Not available
Keywords: The Congress of European Society of Cardiology 2020
References
- Imazio M, Andreis A, Brucato A, et al. Colchicine for acute and chronic coronary syndromes. Heart. 2020; 106(20): 1555–1560.
- Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013; 61(4): 404–410.
- Nidorf SM, Fiolet ATL, Mosterd A, et al. LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020; 383(19): 1838–1847.
- McMurray JV, Solomon S, Inzucchi S, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
- Packer M, Butler J, Filippatos G, et al. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial. Eur J Heart Fail. 2019; 21(10): 1270–1278.
- Heerspink H, Stefansson B, Chertow G, et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020; 35(2): 274–282.
- Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020; 126(10): 1456–1474.
- Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (October 8, 2021).
- Lopes RD, Macedo AV, de Barros E Silva PG, et al. BRACE CORONA investigators. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) — the BRACE CORONA Trial. Am Heart J. 2020; 226: 49–59.
- Packer DL, Mark D, Robb R, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation. JAMA. 2019; 321(13): 1261–1274.
- Nattel S, Guasch E, Savelieva I, et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J. 2014; 35(22): 1448–1456.
- Kirchhof P, Camm AJ, Goette A, et al. EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383(14): 1305–1316.
